Kare has developed a proprietary catalytic process that converts limonene, a sustainable by-product of the citrus industry, into CB1 and CB2 receptor ligands.
A patented catalytic conversion of limonene produces a versatile precursor platform, enabling the rapid synthesis of a diverse library of CB1 and CB2 ligands and structural analogues.
Our platform delivers cGMP-grade compounds for clinical development, meeting and exceeding pharmaceutical industry benchmarks.
Consistent, single-component molecules manufactured without agricultural variability, contamination risk, or batch inconsistency.
Kare Chemical Technologies synthesizes a comprehensive suite of receptor-targeted ligands and novel chemical entities (NCEs) designed for pharmaceutical, and research applications.
High-affinity ligands designed to modulate peripherally restricted receptor pathways relevant to pain and related neurological disorders, limiting or avoiding psychoactive side effects.
Peripheral and centrally mediated receptor modulators with applications towards epilepsy, inflammation, and other CNS conditions including ADHD and anxiety.
Flexible compounds designed for research and development, including tunable analogues, deuterated variants, labeled compounds, preclinical candidates, and custom receptor modulators.
